

Dr. Many compounds exhibit synergistic activity in the investigated cancer cell lines where Dasatinib and the WEE1 kinase inhibitor MK-1775 seemed to be promising candidates for further investigations. During his work at the Molecular Medicine Institute, Dr. Hmeidat explored novel molecularly targeted combination therapies for squamous carcinoma of the head and neck cancer.